Frontiers in urology最新文献

{"title":"Metal urethral stent placement for the management of urethral stricture following phalloplasty: a case report.","authors":"Hu He, Chuanhua Zhong, Qiang Chen, Yongsheng Lei, Longchao Chen, Lulu Li, Xin Zhang, Jinhong Pan, Heng Zhang","doi":"10.3389/fruro.2025.1651449","DOIUrl":"10.3389/fruro.2025.1651449","url":null,"abstract":"<p><strong>Objective: </strong>To report the preliminary experience of a case in which a thermo-expandable nickel-titanium shape memory alloy metal stent was utilized for the management of urethral stricture following phalloplasty.</p><p><strong>Methods: </strong>A 51-year-old male patient underwent lower abdominal island flap phalloplasty due to penile trauma. Postoperative recurrent dysuria occurred, and urethrography revealed stricture at the urethral anastomosis site near the penile root. A thermo-expandable nickel-titanium shape memory alloy metal stent was implanted.</p><p><strong>Results: </strong>The patient underwent a successful surgical procedure. One day after the surgery, the urethral catheter was removed, and the patient resumed normal urination. After achieving satisfactory outcomes, the patient recovered and was discharged. During regular follow-up visits after discharge, the patient maintained unobstructed urination without weak urine stream or other discomforts.</p><p><strong>Conclusions: </strong>The placement of a thermo-expandable nickel-titanium shape memory alloy metal stent offers a novel treatment option for patients with urethral stricture following phalloplasty.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1651449"},"PeriodicalIF":1.1,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the coronavirus disease 2019 (COVID-19) pandemic on tumor stage progression in urological malignancies: a comparative study.","authors":"Alper Keskin, Enis Mert Yorulmaz, Kursad Donmez, Serkan Ozcan, Osman Kose, Sacit Nuri Gorgel, Yigit Akin","doi":"10.3389/fruro.2025.1619185","DOIUrl":"10.3389/fruro.2025.1619185","url":null,"abstract":"<p><strong>Objective: </strong>To determine whether delays in care during the coronavirus pandemic 2019 (COVID-19) were associated with pathological stage progression in urological malignancies by comparing surgical outcomes between pre-pandemic era (PREP) and pandemic-era (POSTP) cohorts.</p><p><strong>Methods: </strong>We conducted a retrospective before-and-after cohort study at a tertiary academic center. A total of 368 patients underwent radical surgeries for prostate (n=176), bladder (n=78), kidney (n=78), or testicular (n=36) cancers between April 2019 and March 2022. Patients were grouped into PREP (April 2019-March 2020) and POSTP (April 2020-March 2022) cohorts. Clinical, laboratory, and pathological data were compared using Student's t-test, Mann-Whitney U test, Chi-square test, or Fisher's exact test, with p<0.05 considered statistically significant.</p><p><strong>Results: </strong>POSTP prostatectomy patients had significantly higher preoperative PSA levels (13.2 ± 16.2 vs. 7.7 ± 4.5 ng/mL, p<0.001), greater tumor involvement (17.0% vs. 11.5%, p=0.019), and increased extraprostatic extension (33.7% vs. 11.9%, p=0.006) compared to PREP patients. Renal tumors were significantly larger during the pandemic (7.4 cm vs. 6.0 cm, p=0.01), and preoperative hemoglobin levels were lower (11.7 vs. 12.9 g/dL, p<0.001), suggesting more advanced disease. No statistically significant differences were observed in pathological staging for bladder or testicular cancers between the two periods (all p>0.05).</p><p><strong>Conclusion: </strong>COVID-19-related care disruptions were associated with adverse pathological features in prostate and renal cancers. In contrast, bladder and testicular cancers showed no significant stage migration. These findings emphasize the need for resilient cancer care pathways to prevent progression during future healthcare crises.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1619185"},"PeriodicalIF":1.1,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12364627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose-rate brachytherapy lowers travel burden for men with localized prostate cancer compared with external beam radiation.","authors":"Catherine Liu, Hongmei Yang, Kevin Bylund, Michael Cummings, Hong Zhang","doi":"10.3389/fruro.2025.1598726","DOIUrl":"10.3389/fruro.2025.1598726","url":null,"abstract":"<p><strong>Objective: </strong>There are many treatment options for localized prostate cancer, including external beam radiation therapy (EBRT), stereotactic body radiation therapy (SBRT), and prostate brachytherapy (BT). This study aimed to compare the travel burdens of high-dose-rate brachytherapy (HDR-BT) at our BT center and EBRT or SBRT if administered close to home.</p><p><strong>Materials and methods: </strong>This single-institution retrospective cohort study included 69 patients who had HDR-BT monotherapy for their prostate cancer from August 2017 to December 2022. The travel burden for HDR-BT monotherapy was estimated using Google Maps by measuring the distance from each patient's home address to our BT center. The total travel burden was calculated by multiplying the number of treatment fractions required for each modality by the roundtrip travel distance between the home and the treatment facility. Treatment toxicity was evaluated using the Expanded Prostate Index Composite for Clinical Practice (EPIC-CP) questionnaire.</p><p><strong>Results: </strong>The median age of the 69 patients was 67 years. The mean distance from home to the BT center was 37.4 mi, while the mean distance to the nearest radiation facility was 8.3 mi. The mean total travel distance for HDR-BT was 150 mi, while those for EBRT and SBRT were 463 and 83 mi, respectively. HDR-BT resulted in a mean travel burden reduction of 313 mi compared with EBRT. The EPIC-CP scores indicated minimal posttreatment toxicity, with most patients reporting stable or improved symptoms.</p><p><strong>Conclusion: </strong>HDR-BT monotherapy significantly reduces the travel burden compared with EBRT for localized prostate cancer, with minimal treatment-associated toxicity. Increasing the availability of BT centers could further alleviate the travel burden. Alternatively, providing transportation support could improve access to care.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1598726"},"PeriodicalIF":1.1,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in real-world research on fertility preservation in men with malignant tumours.","authors":"Dongsheng Ma, Jianhong Xi","doi":"10.3389/fruro.2025.1547589","DOIUrl":"10.3389/fruro.2025.1547589","url":null,"abstract":"<p><p>Malignant tumours have become one of the diseases that seriously threaten human health, and their incidence is increasing year by year. Worldwide, malignant tumours have become one of the most common causes of death in men. With the continuous progress of comprehensive oncological treatment, the cure rate and the survival rate of malignant tumours have been increasing, and the survival cycle has been prolonged, so the issue of fertility preservation in male malignant tumour patients has received widespread attention. In this review, researchers will discuss the real-world research progress related to fertility preservation in male malignant tumour patients, with a view to provide some reference basis for clinical decision-making.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1547589"},"PeriodicalIF":1.1,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unclassifiable renal carcinoma with medullary phenotype and SMARCB1 deficiency: case report.","authors":"Samya H Mehanna, Thiago Gabriel Ronkoski, Cassiano Machado, Lucas S Wolff, Alexandre C Cavalli, Thiago Hota, Fernando C Koleski","doi":"10.3389/fruro.2025.1582675","DOIUrl":"10.3389/fruro.2025.1582675","url":null,"abstract":"<p><strong>Background: </strong>Renal medullary carcinoma (RMC) is an aggressive tumor representing less than 0.5% of renal cell carcinomas (RCC), and it is considered rare. When it occurs, patients typically have sickle cell trait, sickle cell disease, or an associated hemoglobinopathy, which is a necessary characteristic for diagnosis. Additionally, RMC is characterized by the inactivation of alterations in the SMARCB1 (INI1) tumor suppressor gene, resulting in the loss of INI1 immunohistochemical expression. However, there are tumors reported in the literature with the same morphological and phenotypic characteristics as RMC but without hemoglobinopathy, referred to as \"unclassified RCC with medullary phenotype.\"</p><p><strong>Case report: </strong>We present the 13th case of unclassified renal cell carcinoma with a medullary phenotype in a 20-year-old woman. The patient was admitted with complaints of macroscopic hematuria, with no significant findings on physical examination. Diagnostic investigation included a computed tomography urogram, which revealed a hypovascular oval image with central cystic/necrotic areas in the middle third of the right kidney, measuring 32 mm, suggesting a possible diagnosis of an infected renal cyst. Subsequent magnetic resonance imaging showed findings consistent with an atypical presentation of primary neoplasia in the differential diagnosis, prompting a renal biopsy for case definition. Histopathological analysis revealed a high-grade infiltrative epithelioid neoplasm. Immunohistochemistry showed positivity for PAX8 and loss of INI-1 expression. No hemoglobinopathies were identified in the patient, in this context, the neoplasm is appropriately classified as unclassified renal cell carcinoma (RCC) with medullary phenotype and SMARCB1 deficiency. The instituted therapy consisted of right radical nephrectomy with retroperitoneal lymphadenectomy, with nodal metastases detected.</p><p><strong>Conclusion: </strong>Given the rarity of unclassified RCC with a medullary phenotype, continuous documentation and analysis of individual cases not associated with sickle cell trait are crucial to understanding its behavior, prognosis, and potential therapeutic approaches, considering its aggressiveness and high metastatic potential.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1582675"},"PeriodicalIF":1.1,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovations in kidney stone management: mini-PCNL for staghorn calculi in resource-limited settings.","authors":"An Minh Nguyen, Hung Hai Do, Duc Van Nguyen, Long Hoang Vo","doi":"10.3389/fruro.2025.1555624","DOIUrl":"10.3389/fruro.2025.1555624","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluates our initial experience with miniaturized percutaneous nephrolithotomy (mini-PCNL) in Vietnamese patients with staghorn calculi, using an 18F metal access sheath. This technique addresses the challenges of complex kidney stone management in resource-limited settings.</p><p><strong>Methods: </strong>A multi-center retrospective review of 236 patients with staghorn calculi who underwent mini-PCNL with high-power Ho laser lithotripsy (Lumenis 100 W) was conducted at four provincial hospitals in northern Vietnam from January 2020 to December 2023.</p><p><strong>Results: </strong>Among the 236 patients (mean age 54.88 years), 13.56% had prior open surgery, and 3.81% had previous PCNL. Presenting symptoms included flank/back pain (97.88%), acute renal colic (11.44%), and dysuria (5.93%). Right-sided stones were present in 55.93%, left-sided in 32.63%, and bilateral in 11.44%. The mean stone size was 28.05 mm, with 53.81% having stones of 20-30 mm, 38.56% over 30 mm, and 7.63% under 20 mm. Single stones were noted in 69.07%, while 30.93% had multiple stones. The mean stone surface area was 318.17 mm². Hydronephrosis was observed in 53.81% (grade-1: 32.64%; grade-2: 17.37%; grade-3: 3.81%). Postoperative complications included bleeding (13.14%), fever (9.75%), and reoperation or JJ stent placement (1.69%). Stone clearance rates were 67.37% at three days and 80.91% after one month. The mean durations for ureteral catheterization, postoperative hospitalization, and total hospital stay were 3.29, 6.94, and 12.90 days, respectively.</p><p><strong>Conclusions: </strong>Mini-PCNL with high-power Ho laser lithotripsy demonstrates safety and efficacy in managing staghorn calculi, achieving favorable stone clearance and recovery outcomes. This approach offers a viable, cost-effective solution for enhancing access to advanced urological care in resource-constrained environments.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1555624"},"PeriodicalIF":1.1,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of <i>Serenoa repens</i>, lycopene, and selenium versus dutasteride for the treatment of LUTS/BPH: an Italian multicenter case-control prospective study (COMP study).","authors":"Giuseppe Morgia, Arturo Lo Giudice, Sebastiano Cimino, Giulio Reale, Gaetano Larganà, Enza La Manna, Massimo Madonia, Alessandro Tedde, Francesco Santaniello, Giuseppe Vespasiani, Stefano Zaganelli, Salvatore Arnone, Nicola Cruciano, Maurizio Carrino, Francesco Persico, Carlo Terrone, Rafaela Malinaric, Andrea Minervini, Marco Carini, Giorgio Ivan Russo","doi":"10.3389/fruro.2025.1565240","DOIUrl":"10.3389/fruro.2025.1565240","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Historically, medical therapy of BPH has had its foundations in alpha-blockers in monotherapy or in combination with 5 alpha reductase inhibitors (5-ARIs); in particular, two important trials (COMBAT and MTOPS) have demonstrated the pivotal role of combination therapy instead of monotherapy and have individuated which patients are most likely to benefit from alpha-blockers, 5-ARIs, or their combination. However different side effects of these drugs, such erectile dysfunction, ejaculatory disorders, loss of libido, could affect the adherence to treatment. In fact, SeR-Se-Ly would work by blocking 5-alpha reductase and the binding between the dihydrotestosterone and the androgen receptor, antagonizing the a1-adrenergic receptor, and preventing cell proliferation and the production of COX-2 and 5-leukotrienes. Prior randomized controlled trials confirmed the use of alpha-blockers in conjunction with Lipidic Extract (LE) of Serenoa Repens (SeR), specifically compounds containing both Selenium (Se) and Lycopene (Ly). Based on these premises, the aim of this Italian multicenter case-control prospective non-randomized study is to compare the therapy with SeR-Se-Ly alone versus Dutasteride alone against BPH, in order to research a good therapeutic alternative with limited side effects.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;From April 2021 to April 2022, 269 consecutive patients from 21 Italian centers were enrolled in this case-control study. The inclusion criteria were: age between 55 and 80 years old, digital rectal examination negative for prostate nodules, PSA&lt;&lt;4 ng/ml, IPSS&lt;&gt;12, prostate volume &gt;40 cc (assessed by ultrasound), Qmax &lt;&lt;15 ml/sec. Patients with prostate cancer, prior bladder cancer, diabetes mellitus, neurogenic disorders, severe liver disease, history of orthostatic hypotension or syncope, recent a-blocker treatment (within 1 month) or phytotherapy, including saw palmetto extract (within 3 months), prior medical therapy with 5-ARI or surgical treatment for LUTS/BPH, patients with catheter or QoL, Qmax measured at an episode of acute urine retention within the last 4 weeks, and patients with any ejaculatory disorders were excluded. During treatment period, patients received SeR-Se-Ly for one year (Group A), or Dutasteride 0.5mg for one year (Group B). The main outcome measures included International Prostatic Symptoms Score (IPSS) and IPSS quality-of -life (QoL), International Index of Erectile Function (IIEF-5), Qmax measured at uroflowmetry and the Male Sexual Health Questionnaire (MSHQ).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We have observed increasing of Qmax of 2 points in group A and 2,5 points group B; IPSS has been reduced of 4 points in group A and 4,5 points in group B; IIEF-5 didn't change in group A and it has been reduced in group B by -1; regarding the MSHQ, only the item MSHQ-Satisfaction has changed in group A: -1, in group B MSHQ was reduced by -2 points in ED, by -5 points in EJ, by","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1565240"},"PeriodicalIF":1.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing access to care in a postpartum pelvic floor healing clinic.","authors":"Anya Singh-Varma, Li Wang, Rachel Durst, Pamela A Moalli, Lauren E Giugale","doi":"10.3389/fruro.2025.1548341","DOIUrl":"10.3389/fruro.2025.1548341","url":null,"abstract":"<p><strong>Introduction: </strong>Disparities in pregnancy care exist in the United States, with limited data on access to specialized postpartum care for patients with complicated perineal lacerations. Our objective was to assess for disparities in access to a postpartum pelvic floor healing clinic following vaginal delivery. We hypothesized an underrepresentation of patients from more resource-deprived neighborhoods and those with longer travel times to the specialized clinic.</p><p><strong>Methods: </strong>This is a retrospective cohort study comparing sociodemographic variables from a historical cohort of patients with third- and fourth-degree lacerations following vaginal delivery to a cohort of patients evaluated in a postpartum pelvic floor healing clinic. The primary outcome involved the comparison of the neighborhood area deprivation index between groups. The secondary outcomes included median household income, driving time, and distance to the hospital.</p><p><strong>Results: </strong>Patients seen in the postpartum pelvic floor healing clinic were older (31.3 vs. 29.9 years, <i>p</i> < 0.01) and more likely to be multiparous (20.3% vs. 13.1%, <i>p</i> = 0.04). Race, ethnicity, and operative vaginal delivery were similar between groups. Patients from the postpartum pelvic floor healing clinic had more postpartum visits [3 (IQR 2-4) vs. 2 (IQR 1-2) visits, <i>p</i> < 0.01]. There was no significant difference in median neighborhood area deprivation indices [4 (IQR 2-7) vs. 5 (IQR 3-7), <i>p</i> = 0.06]. Fewer patients from the most resource-deprived neighborhoods were seen in the postpartum pelvic floor healing clinic, though this was not statistically significant (4.5% vs. 8.9%, <i>p</i> = 0.06). There were no significant differences in median household income or driving distance to the hospital between groups.</p><p><strong>Conclusions: </strong>Access to a specialized postpartum pelvic floor healing clinic at our institution appears equitable across several sociodemographic factors.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1548341"},"PeriodicalIF":1.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the prevalence of pediatric lower urinary tract symptoms in a national claims database of privately insured patients, 2007-2016.","authors":"Raphael James Brosula, Pranaya Venkatapuram, Abby L Chen, Chiyuan A Zhang, Kathleen M Kan","doi":"10.3389/fruro.2025.1422897","DOIUrl":"10.3389/fruro.2025.1422897","url":null,"abstract":"<p><strong>Background: </strong>Pediatric lower urinary tract symptoms (LUTS) impact a significant number of children and families worldwide. Estimated prevalences rely on small cross-sectional studies, leading to inconsistent estimates. This study aims to characterize demographic and temporal trends in LUTS prevalence within a national claims database of privately insured individuals in the United States.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study by reviewing the Merative™ MarketScan^® Outpatient Research Database v2.0 between 2007-2016. Patients with neurogenic bladder, renal transplant, structural urologic disease, and concurrent urinary tract infection were excluded. Yearly trends were reviewed across age, sex, geographic region, and clinical comorbidities such as attention-deficit/hyperactivity disorder (ADHD) and constipation. Yearly frequency of diagnostic codes was calculated to characterize LUTS diagnostic coding practices.</p><p><strong>Results: </strong>We identified 1,625,538 patients aged 5-18 years with LUTS, representing 6% of the total population at risk, with a median age of 8.0 years. More patients in the cohort were female (66.1%), between 5-10 years old (57.9%), and resided in the Southern US (38.5%). The yearly prevalence of LUTS significantly increased from 1.8% to 2.1% yearly, and saw significant increases in females, 15-18 year old patients, and across several geographic regions. Comorbid constipation and ADHD within LUTS patients also significantly increased. Diagnostic coding practices remained stable.</p><p><strong>Conclusions: </strong>Families of patients with LUTS are increasingly seeking medical care for their condition. These results exceed similar estimates from previous longitudinal studies and can inform population-level intervention strategies. Further studies should investigate the impact of LUTS on healthcare resource utilization, including in non-privately insured populations.</p>","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1422897"},"PeriodicalIF":1.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and impact of sarcopenia on urinary incontinence in localized prostate cancer patients undergoing laparoscopic radical prostatectomy.","authors":"Tengfei Gu, Jie Li, Dan Wu, Ting Chen, Yongtao Pan, Qinzhou Yu, Jing Sha","doi":"10.3389/fruro.2025.1567575","DOIUrl":"10.3389/fruro.2025.1567575","url":null,"abstract":"<p><strong>Objective: </strong>This research seeks to assess the prevalence of sarcopenia in patients diagnosed with localized prostate cancer and to investigate the influence of sarcopenia on the incidence of urinary incontinence following laparoscopic radical prostatectomy.</p><p><strong>Methods: </strong>A cohort of 350 patients, diagnosed with prostate cancer and having undergone laparoscopic radical prostatectomy at our hospital's urology department between January 2022 and December 2023, was selected for this study. The cohort comprised 215 patients classified as low to intermediate risk and 135 patients classified as high risk. Participants were categorized into two groups: the sarcopenia group (n = 143) and the non-sarcopenia group (n = 207). The study aimed to summarize the prevalence of sarcopenia among patients with localized prostate cancer and to compare the incidence of urinary incontinence immediately post-surgery, as well as at three and six months postoperatively, between the sarcopenia and non-sarcopenia groups.</p><p><strong>Results: </strong>The study assessed the prevalence of sarcopenia in a cohort of 350 patients with localized prostate cancer, revealing an overall prevalence rate of 40.86%. Specifically, the prevalence was 34.2% among patients classified as low to intermediate risk and 51.11% among those classified as high risk (P<0.01). The incidence rates of urinary incontinence were documented at various postoperative intervals: immediately after surgery, at 3 months, and at 6 months, with rates of 72%, 47.81%, and 28%, respectively. Notably, patients with sarcopenia exhibited significantly higher urinary incontinence rates compared to those without sarcopenia, at 82.52%, 65.03%, and 37.06% versus 64.73%, 35.75%, and 21.74% (P<0.01). Among low to intermediate-risk patients, the urinary incontinence rates immediately post-surgery, at 3 months, and at 6 months were 59.53%, 32.56%, and 16.28%, respectively, which were significantly lower than the rates observed in high-risk patients, recorded at 91.85%, 71.85%, and 46.67% (P<0.01). In the subgroup of low to intermediate-risk patients with sarcopenia, the postoperative urinary incontinence rates were 68.92% immediately, 54.05% at 3 months, and 18.92% at 6 months, compared to 54.61%, 21.28%, and 14.89% in patients without sarcopenia. However, the differences in incontinence rates immediately post-surgery and at 6 months were not statistically significant (P>0.05)In patients at high risk with sarcopenia, the incidence rates were 97.10%, 76.81%, and 56.52%, which were higher compared to those without sarcopenia, who exhibited rates of 86.36%, 66.67%, and 36.36%. There was no significant difference observed at three months post-surgery (P > 0.05). Regression analysis indicates that sarcopenia is significantly associated with an increased risk of urinary incontinence following radical prostatectomy at three months post-operation (OR = 0.448, 95% CI: 0.290-0.691, P < 0.001) and s","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":"5 ","pages":"1567575"},"PeriodicalIF":1.1,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}